Hosted on MSN1mon
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK InhibitorsRegor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback